Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)

References

• Anderson VR, Keating GM. Dalbavancin. Drugs. 2008;68(5):649–651.
   Google Scholar
• Gupta AK, Foley KA, Abramovits W, et al. Dalbavancin (Dalvance) for the treatment of acute bacterial skin infection. Skinmed. 2014;12(6):366–369.
   PubMedGoogle Scholar
• Dunne MW, Puttagunta S, Sprenger CR, et al. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849–1855.
   PubMed Web of Science ®Google Scholar
• Chen AY, Zervos MJ, Vazquez JA. Dalbavancin: a novel antimicrobial. Int J Clin Pract. 2007;61(5):853–863.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Peghin M, Carnelutti A, et al. The role of dalbavancin in skin and soft tissue infections. Curr Opin Infect Dis. 2018;31(2):141–147.
   PubMed Web of Science ®Google Scholar
• Leuthner KD, Buechler KA, Kogan D, et al. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag. 2016;12:931–940.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Talbot GH, Boucher HW, et al. Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies. Drug Saf. 2016;39(2):147–157.
   PubMed Web of Science ®Google Scholar
• Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37(10):1298–1303.
   PubMed Web of Science ®Google Scholar
• Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48(3):940–945.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545–551.
   PubMed Web of Science ®Google Scholar
• Krsak M, Morrisette T, Miller M, et al. Advantages of outpatient treatment with long-acting lipoglycopeptides for serious gram-positive infections: a review. Pharmacotherapy. 2020;40(5):469–478.
   PubMed Web of Science ®Google Scholar
• Almangour TA, Perry GK, Terriff CM, et al. Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility. Diagn Microbiol Infect Dis. 2019;93(3):213–218.
   PubMed Web of Science ®Google Scholar
• Morata L, Cobo J, Fernández-Sampedro M, et al. Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. Antimicrob Agents Chemother. 2019;63(5). DOI:10.1128/AAC.02280-18
   PubMed Web of Science ®Google Scholar
• Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. Clin Infect Dis. 2018;67(5):795–798.
   PubMed Web of Science ®Google Scholar
• Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2019;6(1):ofy331.
   PubMed Web of Science ®Google Scholar
• Bouza E, Valerio M, Soriano A, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51(4):571–577.
   PubMed Web of Science ®Google Scholar
• Dinh A, Duran C, Pavese P, et al. French national cohort of first use of dalbavancin: a high proportion of off-label use. Int J Antimicrob Agents. 2019;54(5):668–672.
   PubMed Web of Science ®Google Scholar
• Kussmann M, Karer M, Obermueller M, et al. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Emerg Microbes Infect. 2018;7(1):202.
   PubMedGoogle Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–2179.
   PubMed Web of Science ®Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41(10):1407–1415.
   PubMed Web of Science ®Google Scholar
• Tobudic S, Forstner C, Burgmann H, et al. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. Infection. 2019;47(6):1013–1020.
   PubMed Web of Science ®Google Scholar
• Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life dalbavancin use in gram-positive infections. Int J Infect Dis. 2019;81:210–214.
   PubMed Web of Science ®Google Scholar
• Kock R, Friedrich A. On behalf of the original author Group C. Systematic literature analysis and review of targeted preventive measures to limit healthcare-associated infections by meticillin-resistant Staphylococcus aureus. Euro Surveill. 2014 Jul 24;19(29):20860. .DOI: 10.2807/1560-7917.es2014.19.29.20860
   Google Scholar
• Bork JT, Heil EL, Berry S, et al. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections. Infect Dis Ther. 2019;8(2):171–184.
   PubMed Web of Science ®Google Scholar
• Bryson-Cahn C, Beieler AM, Chan JD, et al. Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population. Open Forum Infect Dis. 2019;6(2):ofz028.
   PubMed Web of Science ®Google Scholar
• Patel M, Smalley S, Dubrovskaya Y, et al. Dalbavancin use in the emergency department setting. Ann Pharmacother. 2019;53(11):1093–1101.
   PubMed Web of Science ®Google Scholar
• Ciccullo A, Giuliano G, Segala FV, et al. Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection. Infection. 2020;48(2):309–310.
   PubMed Web of Science ®Google Scholar
• Bartoletti M, Mikus E, Pascale R, et al. Clinical experience with dalbavancin for the treatment of deep sternal wound infection. J Glob Antimicrob Resist. 2019;18:195–198.
   PubMed Web of Science ®Google Scholar
• Hakim A, Braun H, Thornton D, et al. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: a case report. Int J Infect Dis. 2020;91:202–205.
   PubMed Web of Science ®Google Scholar
• Hidalgo-Tenorio C, Vinuesa D, Plata A, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019;18(1):30.
   PubMed Web of Science ®Google Scholar
• Buzón Martín L, Mora Fernández M, Perales Ruiz JM, et al. Dalbavancin for treating prosthetic joint infections caused by gram-positive bacteria: a proposal for a low dose strategy. A retrospective cohort study. Rev Esp Quimioter. 2019;32(6):532–538.
   PubMed Web of Science ®Google Scholar
• Howard-Anderson J, Pouch SM, Sexton ME, et al. Left ventricular assist device infections and the potential role for dalbavancin: a case report. Open Forum Infect Dis. 2019;6(9):ofz235.
   PubMed Web of Science ®Google Scholar
• Golan Y. Current treatment options for acute skin and skin-structure infections. Clin Infect Dis. 2019;68(Suppl 3):S206–S212.
   PubMedGoogle Scholar
• Streifel AC, Sikka MK, Bowen CD, et al. Dalbavancin use in an academic medical centre and associated cost savings. Int J Antimicrob Agents. 2019;54(5):652–654.
   PubMed Web of Science ®Google Scholar
• Knafl D, Tobudic S, Cheng SC, et al. Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Eur J Clin Microbiol Infect Dis. 2017;36(4):677–680.
   PubMed Web of Science ®Google Scholar
• Murillo Ó, El-Haj C. [Analysis of dalbavancin in animal models]. Enferm Infecc Microbiol Clin. 2017;35(Suppl 1):28–32.
   PubMedGoogle Scholar
• Barnea Y, Lerner A, Aizic A, et al. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. J Antimicrob Chemother. 2016;71(2):460–463.
   PubMed Web of Science ®Google Scholar
• Wilke M, Worf K, Preisendörfer B, et al. Potential savings through single-dose intravenous dalbavancin in long-term MRSA infection treatment – a health economic analysis using German DRG data. GMS Infect Dis. 2019;7:Doc03.
   PubMedGoogle Scholar
• McCarthy MW, Keyloun KR, Gillard P, et al. Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial. Infect Dis Ther. 2019;9(1):53–67.
   PubMed Web of Science ®Google Scholar
• Azamgarhi T, Donaldson J, Shah A, et al. Dalbavancin to treat infected massive endoprostheses: a case report and cost comparison analysis. J Bone Jt Infect. 2019;4(5):234–237.
   PubMedGoogle Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10–52.
   PubMed Web of Science ®Google Scholar